Genfit Other Current Liab Over Time
| GNFT Stock | USD 4.21 0.06 1.41% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Genfit Performance and Genfit Correlation. Genfit |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genfit. If investors know Genfit will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genfit listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.39 | Revenue Per Share 1.619 | Quarterly Revenue Growth 3.044 | Return On Assets 0.0651 | Return On Equity 0.2591 |
The market value of Genfit is measured differently than its book value, which is the value of Genfit that is recorded on the company's balance sheet. Investors also form their own opinion of Genfit's value that differs from its market value or its book value, called intrinsic value, which is Genfit's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genfit's market value can be influenced by many factors that don't directly affect Genfit's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Genfit's value and its price as these two are different measures arrived at by different means. Investors typically determine if Genfit is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genfit's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Other Current Liab Analysis
Compare Genfit and related stocks such as Cyteir Therapeutics, Erytech Pharma SA, and Eliem Therapeutics Other Current Liab Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCWB | 673.8 K | 673.8 K | 673.8 K | 673.8 K | 673.8 K | 673.8 K | 673.8 K | 673.8 K | 673.8 K | 673.8 K | 278.4 K | 2.1 M | 1.7 M | 2.6 M | 1.6 M |
| MOLN | 1.0 | 1.0 | 1.0 | 1.0 | 3.2 M | 3.1 M | 4.3 M | 4.5 M | 6.9 M | 7 M | 9.4 M | 11.6 M | 15.1 M | 12.8 M | 7.8 M |
| MNOV | 432.1 K | 2.1 M | 542.8 K | 426.5 K | 1.1 M | 1.3 M | 1.3 M | 1.4 M | 1.6 M | 1.8 M | 1.6 M | 2.3 M | 2.6 M | 2.1 M | 1.6 M |
| ANEB | 22.6 K | 22.6 K | 22.6 K | 22.6 K | 22.6 K | 22.6 K | 22.6 K | 22.6 K | 22.6 K | 22.6 K | 131.6 K | 131.7 K | 534.3 K | 104.2 K | 203.3 K |
| CSBR | 210 K | 625 K | 611 K | 587 K | 373 K | 271 K | 685 K | 595 K | 1.2 M | 2.5 M | 2.2 M | 1.4 M | 1.2 M | 973 K | 739.7 K |
| KROS | 802 K | 802 K | 802 K | 802 K | 802 K | 802 K | 802 K | 802 K | 802 K | 107 K | 4 M | 6.4 M | 12.2 M | 17.9 M | 18.8 M |
| JANX | 360 K | 360 K | 360 K | 360 K | 360 K | 360 K | 360 K | 360 K | 360 K | 360 K | 803 K | 4.8 M | 7.4 M | 7.4 M | 4.6 M |
| FENC | 30.4 K | 5.1 M | 7.1 M | 3 M | 1.5 M | 174 K | 158 K | 789 K | 605 K | 659 K | 776 K | 877 K | 2.2 M | 3.8 M | 2.1 M |
| EWTX | 465 K | 465 K | 465 K | 465 K | 465 K | 465 K | 465 K | 465 K | 465 K | 465 K | 2.8 M | 6.7 M | 9.3 M | 10.8 M | 6.6 M |
| HRMY | 5.8 M | 5.8 M | 5.8 M | 5.8 M | 5.8 M | 5.8 M | 5.8 M | 5.8 M | 5.8 M | 13.5 M | 132 M | 50.8 M | 73.1 M | 131.1 M | 74.5 M |
| AVTE | 115 K | 115 K | 115 K | 115 K | 115 K | 115 K | 115 K | 115 K | 115 K | 115 K | 1.2 M | 958 K | 4.4 M | 14.4 M | 15.1 M |
| ADAG | 7.4 M | 7.4 M | 7.4 M | 7.4 M | 7.4 M | 7.4 M | 7.4 M | 7.4 M | 7.4 M | 4.4 M | 8.5 M | 14.8 M | 22.2 M | 19.7 M | 14.1 M |
| ACRV | 419 K | 419 K | 419 K | 419 K | 419 K | 419 K | 419 K | 419 K | 419 K | 419 K | 419 K | 1.2 M | 4.1 M | 6.5 M | 3.4 M |
| RZLT | 157.8 K | 157.8 K | 157.8 K | 35.6 K | 130.4 K | 131.6 K | 588 | 73.9 K | 7.3 M | 2.1 M | 403 K | 1.2 M | 1.4 M | 4.1 M | 4.3 M |
| ANTX | 108 K | 108 K | 108 K | 108 K | 108 K | 108 K | 108 K | 108 K | 108 K | 108 K | 1.3 M | 2.3 M | 5 M | 11.4 M | 11.9 M |
Genfit and related stocks such as Cyteir Therapeutics, Erytech Pharma SA, and Eliem Therapeutics Other Current Liab description
My Equities
My Current Equities and Potential Positions
Additional Tools for Genfit Stock Analysis
When running Genfit's price analysis, check to measure Genfit's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genfit is operating at the current time. Most of Genfit's value examination focuses on studying past and present price action to predict the probability of Genfit's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genfit's price. Additionally, you may evaluate how the addition of Genfit to your portfolios can decrease your overall portfolio volatility.